Ketamine inhibits tumor necrosis factor-α and interleukin-6 gene expressions in lipopolysaccharide-stimulated macrophages through suppression of toll-like receptor 4-mediated c-Jun N-terminal kinase phosphorylation and activator protein-1 activation
- 1 April 2008
- journal article
- Published by Elsevier BV in Toxicology and Applied Pharmacology
- Vol. 228 (1), 105-113
- https://doi.org/10.1016/j.taap.2007.11.027
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Cooperation of Toll-like receptor signals in innate immune defenceNature Reviews Immunology, 2007
- Ketamine Attenuates Early Lipopolysaccharide-Induced Gastric Dysfunction: Role of Stress-Inducible PhosphoproteinsJournal Of Trauma-Injury Infection and Critical Care, 2007
- Pretreatment with low nitric oxide protects osteoblasts from high nitric oxide‐induced apoptotic insults through regulation of c‐Jun N‐terminal kinase/c‐Jun‐mediated Bcl‐2 gene expression and protein translocationJournal of Orthopaedic Research, 2007
- Tumor Necrosis Factor Inhibitors for Rheumatoid ArthritisNew England Journal of Medicine, 2006
- Pathogen Recognition and Innate ImmunityCell, 2006
- Suppressive effects of ketamine on macrophage functionsToxicology and Applied Pharmacology, 2004
- Safety of sedation with ketamine in severe head injury patients: Comparison with sufentanilCritical Care Medicine, 2003
- Studies on the role of tumor necrosis factor inmurine and human autoimmunityJournal of Autoimmunity, 1992
- The Molecular Regulators of Macrophage and Granulocyte DevelopmentAnnals of the New York Academy of Sciences, 1989
- Ketamine: an update on the first twenty-five years of clinical experienceCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1989